Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer, Johnson and...

    Bayer, Johnson and Johnson win reversal of 28 million dollars verdict in Xarelto lawsuit

    Written by Ruby Khatun Khatun Published On 2018-01-11T10:15:11+05:30  |  Updated On 16 Aug 2021 11:19 AM GMT

    A Pennsylvania state court judge on Tuesday overturned a $27.8 million jury award to an Indiana couple who accused Bayer AG and Johnson and Johnson of failing to warn of internal bleeding risks of their drug Xarelto, the companies said.


    Judge Michael Erdos, in the Philadelphia County Court of Common Pleas, ruled following a hearing on the drugmakers' motion to reverse the December verdict, which was their first trial loss in litigation over the blood thinner, the companies said.


    J&J's Janssen Pharmaceuticals Inc unit and Bayer, which jointly developed Xarelto, in separate statements welcomed the decision and said they will continue to defend against the allegations in related litigation.


    "Bayer stands behind the safety and efficacy of Xarelto and will continue to vigorously defend it," Bayer said in a statement.



    The verdict came in a lawsuit by Lynn Hartman, who was prescribed Xarelto to prevent strokes as a result of atrial fibrillation, an irregular heartbeat.

    Hartman said that she took the drug for approximately one year and in June 2014 was hospitalized with severe gastrointestinal bleeding, which she blamed on Xarelto. She has since recovered.


    Hartman and her husband sued the drugmakers in 2015. A jury in December awarded $1.8 million in compensatory damages and $26 million in punitive damages.


    The lawsuit was one of around 21,400 that J&J says are pending in federal and state courts blaming injuries on Xarelto. The trial was the first to result from roughly 1,400 Xarelto cases pending in the Philadelphia court.


    Michael Weinkowitz, a lawyer for the couple, said the decision related to a "very narrow issue related to Mrs. Hartman's prescribing physician." He said he looked forward to trying the next series of Xarelto-related cases in Philadelphia.


    The U.S. Food and Drug Administration approved Xarelto in 2011. It is prescribed for people with atrial fibrillation, a common heart rhythm disorder, and to treat and reduce the risk of deep vein thrombosis and pulmonary embolisms.

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    But plaintiffs contend Xarelto was unreasonably dangerous and that J&J and Bayer failed to warn patients about a serious risk of uncontrollable, irreversible bleeding in emergencies.


    Bayer and J&J contend Xarelto's label adequately warns of bleeding risks.


    Federal juries have cleared the companies of liability in three previous trials. The latest verdict in the federal litigation came in August in the case of a Mississippi woman.




    (Reporting by Nate Raymond in Boston; Editing by Leslie Adler)



    Bayer internal bleeding risks Janssen Pharmaceuticals Inc Johnson and Johnson Judge Michael Erdos lawsuit Lynn Hartman pharma news reversal U.S. Food and Drug Administration verdict win Xarelto 
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X